Optimized monoclonal antibody panel for accurate immunohistochemical detection of haematopoietic cell populations in animal species Authors: Lorena Maestre, Eduardo Caleiras, Ana Isabel Reyes-García, Zaira Vega, Scherezade Jiménez, Carmen San Juan-Casero, Patricia González, Eva Martínez-Nevado, Juncal García-García, María de los Ángeles Jiménez-Martínez, Claudia Pérez-Martínez, Julio Benavides-Silván, Dolores C. García-Olmo, Carlota Largo-Aramburu, Antonio de Molina-Iracheta, Santiago Borragán, Karen Pulford, Giovanna Roncador Published: 2026 ABSTRACT BackgroundImmunohistochemistry (IHC) has emerged as an essential tool in characterizing neoplastic diseases, playing a crucial role in both human and veterinary medicine. Despite the increased demand for specific diagnoses in veterinary oncology, the full potential of IHC has been hampered by the reduced number of specific cross-reactive antibodies recognising their antigens in diverse animal species. This study addresses this limitation by testing the cross-reactivity of a panel of 69 antibodies, including one in-house generated monoclonal antibody, using IHC on routinely fixed formalin-fixed paraffin-embedded tissues of lymph node, spleen or bursa of Fabricius samples from domestic (n = 13) and exotic/wild (n = 28) animal species as well as normal human lymph node.ResultsWe successfully identified a panel of 16 monoclonal or multiclonal antibodies targeting lymphoid (CD3, CD4, CD8, FOXP3, PD-1, TOX2, CD19, CD20, CD21, CD79a, CD79b, BCL-2, BCL-6, IRF-4, PAX5) and myeloid (CD163) antigens that are cross reactive across species. This comprehensive panel enables the precise detection of the most important subpopulations of haematopoietic cells, including T and B cells, macrophages and dendritic cells.ConclusionsThe results improve the availability of antibodies for immunohistochemical studies in veterinary clinical practice and research. The cross-reactive antibody panel identified here is a versatile tool for further studies in immunophenotyping immune cell populations in diverse animal species. It represents a significant advance toward improved diagnostic accuracy in veterinary medicine, facilitating the study of these cell populations under normal and pathological conditions.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12917-026-05450-7. Background The use of antibodies specific for haematopoietic cells combined with immunohistochemical techniques has resulted in pivotal advances in human pathology. The accurate identification and characterization of immune cell subpopulations using IHC on routinely fixed formalin-fixed paraffin-embedded (FFPE) tissue specimens has significantly advanced the pathological assessment of lymphomas and their associated tumour microenvironment [1, 2]. As has been extensively demonstrated in human pathology, the development and validation of monoclonal antibodies initially tested in non-neoplastic tissues represent a crucial first step toward their application in pathological conditions. Once validated in normal tissues, these antibodies can be reliably employed to study cellular phenotypes in neoplastic and inflammatory processes, enabling more accurate diagnosis, improved disease classification, and, in selected cases, the identification of prognostic or therapeutic targets. Applying this established paradigm to veterinary medicine expands the possibilities for immunophenotypic characterization of diseases across animal species and provides a translational framework through which advances in human pathology can be effectively applied to veterinary diagnostics. However, further investigation in neoplastic and inflammatory conditions will be necessary to assess the diagnostic and prognostic utility of this antibody panel in veterinary pathology. The use of IHC in veterinary pathology has been restricted by the availability of antibodies and suitable tissue fixation techniques. Many of the antibodies used in human studies may, however, also be suitable for veterinary use [3] and Table 1 lists some antigens expressed on immune cells which have been studied in a limited number of IHC studies on animal tissues. Table 1Details of IHC studies of haematopoietic antigens studied in animal speciesMarkerMoleculeExpressionSpecies studiedReferencesCD3Cell surface receptorThymocytes, peripheral T cellsMonkey, pig, horse, rabbit, cow, guinea pig, rat, mouse, opossum, chicken, sheep, pig, bird, dog, cat, harbour seal, walrus, dolphin and camelid[4–13]CD4Cell surface receptorT helper cellsMonkey, pig, horse, rabbit, cow, guinea pig, rat, mouse, opossum, chicken, sheep and dog[6, 9, 14]CD8Cell surface receptorSuppressor/cytotoxic T-cellsSheep, bird, dog and cow[5, 6, 9, 15]FOXP3Transcription factorRegulatory T cellsSheep, dog, horse, cat, pig, deer, harbour seal, walrus, dolphin and alpaca[12, 13, 16, 17]PD-1Cell surface receptorFollicular helper T cells. Activated/exhausted CD8 + T cells and B cells and monocytesDog and sheep[18–20]TOX2Transcription factorFollicular helper T cells and NK cellsHuman[21]CD19Cell surface receptorB cells from early stages of development to maturity, but absent in plasma cellsPig and dog[22–24]CD20Cell surface receptorB cells from early stages of development to mature B cells but absent in plasma cellsDog and camellid[8, 25]CD21Cell surface receptorMature B cell and follicular dendritic cellsHorse[26]CD79aCell surface receptorB cells throughout most stages of development, from early committed B cells to mature B cells, including plasma cellsMonkey, pig, horse, rabbit, cow, guinea pig, rat, mouse, opossum, seal, walrus and chicken[4, 5, 7, 8, 12, 17]CD79bCell surface receptorB cells throughout most stages of development to maturity but absent in plasma cellsMonkey, pig, horse, rabbit, cow, guinea pig, rat, mouse, opossum, chicken, bird and deer[4, 7]BCL-2Intracellular proteinT-cells, pro-B cells and mature B-cells (where lifespan is extended) while downregulated in germinal centre B-cellsCat[27, 28]BCL-6Transcription factorGerminal centre B cells and some T cellsDog, mouse and rat[10, 29]MUM1/IRF-4Transcription factorB cells at late differentiation stages and in plasma cellsDog, mouse and rat[10, 30]PAX5Transcription factorB cells from early development to maturity but absent in plasma cellsSheep, dog, cat, mouse and rat[6, 10, 11, 31]CD163Cell surface receptorMonocyte/macrophage lineageHorse, sheep and deer[6, 17, 32] Table 1Details of IHC studies of haematopoietic antigens studied in animal speciesMarkerMoleculeExpressionSpecies studiedReferencesCD3Cell surface receptorThymocytes, peripheral T cellsMonkey, pig, horse, rabbit, cow, guinea pig, rat, mouse, opossum, chicken, sheep, pig, bird, dog, cat, harbour seal, walrus, dolphin and camelid[4–13]CD4Cell surface receptorT helper cellsMonkey, pig, horse, rabbit, cow, guinea pig, rat, mouse, opossum, chicken, sheep and dog[6, 9, 14]CD8Cell surface receptorSuppressor/cytotoxic T-cellsSheep, bird, dog and cow[5, 6, 9, 15]FOXP3Transcription factorRegulatory T cellsSheep, dog, horse, cat, pig, deer, harbour seal, walrus, dolphin and alpaca[12, 13, 16, 17]PD-1Cell surface receptorFollicular helper T cells. Activated/exhausted CD8 + T cells and B cells and monocytesDog and sheep[18–20]TOX2Transcription factorFollicular helper T cells and NK cellsHuman[21]CD19Cell surface receptorB cells from early stages of development to maturity, but absent in plasma cellsPig and dog[22–24]CD20Cell surface receptorB cells from early stages of development to mature B cells but absent in plasma cellsDog and camellid[8, 25]CD21Cell surface receptorMature B cell and follicular dendritic cellsHorse[26]CD79aCell surface receptorB cells throughout most stages of development, from early committed B cells to mature B cells, including plasma cellsMonkey, pig, horse, rabbit, cow, guinea pig, rat, mouse, opossum, seal, walrus and chicken[4, 5, 7, 8, 12, 17]CD79bCell surface receptorB cells throughout most stages of development to maturity but absent in plasma cellsMonkey, pig, horse, rabbit, cow, guinea pig, rat, mouse, opossum, chicken, bird and deer[4, 7]BCL-2Intracellular proteinT-cells, pro-B cells and mature B-cells (where lifespan is extended) while downregulated in germinal centre B-cellsCat[27, 28]BCL-6Transcription factorGerminal centre B cells and some T cellsDog, mouse and rat[10, 29]MUM1/IRF-4Transcription factorB cells at late differentiation stages and in plasma cellsDog, mouse and rat[10, 30]PAX5Transcription factorB cells from early development to maturity but absent in plasma cellsSheep, dog, cat, mouse and rat[6, 10, 11, 31]CD163Cell surface receptorMonocyte/macrophage lineageHorse, sheep and deer[6, 17, 32] Details of IHC studies of haematopoietic antigens studied in animal species There remains, however, an urgent need in veterinary medicine and research for antibodies that can be used to accurately immunophenotype cell populations and that can cross react with their target antigens in tissues from multiple animal species. Guidelines have been published for the standardisation of immunohistochemistry and immunocytochemistry in veterinary medicine [33–36] highlighting the important role of well characterised antibody panels in ensuring reproducible and interpretable results. We also emphasize that classical antibody validation strategies routinely applied in human and laboratory rodent species, such as the use of knockout or knockdown tissues, genetically engineered cell lines, and protein-level confirmation by Western blotting, are often not feasible in wild/exotic or non-model animals. Accordingly, the interpretation of immunohistochemical results in this study is based on conserved morphological features, expected cell-type specific localization consistent with vertebrate biology, and comparison with staining patterns observed in validated human tissues, supported by expert pathological assessment. The goal of the current study was to assess the success of commercially available and ‘in house’ produced antibody, originally designed to detect haematopoietic cell subpopulations in humans, in identifying immune cells from 41 animal species. We focused on the use of IHC in FFPE tissue samples from lymph nodes, spleens and bursa of Fabricius to lay a robust foundation for future research on this subject. Methods Materials To ensure a comprehensive cross-species analysis, the study incorporated a wide range of domestic and wild/exotic animals. The domestic species examined were the mouse (Mus musculus), rat (Rattus norvegicus), cat (Felis catus), dog (Canis lupus familiaris), horse (Equus ferus), pig (Sus scrofa domesticus), llama (Lama glama), cow (Bos taurus), goat (Capra aegagrus), sheep (Ovis orientalis), chicken (Gallus gallus domesticus), tumbler pigeon (Columba livia domestica) and canary (Serinus canaria). Wild and exotic species included primates such as the baboon (Papio sp.), mandrill (Mandrillus sphinx), bornean gibbon (Hylobates muelleri) and brown lemur (Eulemur fulvus mayottensis); rodents such as the patagonian mara (Dolichotis patagonum); carnivores including the badger (Meles meles), giant otter (Pteronura brasiliensis), raccoon (Procyon lotor), Asian black bear (Ursus thibetanus) and grey wolf (Canis lupus occidentalis); and a variety of ungulates including the South American sea lion (Otaria byronia), reindeer (Rangifer tarandus), Chinese muntjac (Muntiacus reevesi), fallow deer (Dama dama), wild boar (Sus scrofa), red river hog (Potamochoerus porcus), European bison (Bison bonasus), sitatunga (Tragelaphus spekii) and dorcas gazelle (Gazella dorcas neglecta). Avian species studied included the emu (Dromaius novaehollandiae), black swan (Cygnus atratus), Jacobin pigeon (Columba livia), American flamingo (Phoenicopterus ruber), black-footed penguin (Spheniscus demersus), white stork (Ciconia ciconia), sacred ibis (Threskiornis aethiopicus), common barn owl (Tyto alba) and snowy owl (Bubo scandiacus), see Supplementary Table 1. Tissue from all the species, that includes lymph node, spleen and bursa of Fabricius, were kindly provided from different Spanish Institutions: Faculty of Veterinary Medicine-University of León (León), Instituto de Ganadería de Montaña (IGM, Leon), Science and Applied Experimental Biomedical Research Centre (CREBA, Lleida), Instituto de Parasitología y Biomedicina (IPB, Granada), Experimental Surgery Unit of La Paz Hospital (Madrid) and Spanish National Cancer Research Centre (CNIO, Madrid). All the wild and exotic specimens were kindly supplied by the Zoo Aquarium Madrid (Madrid). One representative lymphoid tissue sample was examined per species (total N = 41; see Supplementary Table 1), as the primary aim was to assess antibody cross-reactivity across a broad range of species rather than inter-individual variability. Sample availability for wild and exotic species, was inherently limited due to the post-mortem collection and restricted number of animals available for these species. All samples analysed in this study were obtained post-mortem from animals that died of unrelated causes. In all cases, the lymphoid tissues were evaluated by our pathologist, who confirmed the absence of neoplastic disease. Samples showing evidence of neoplasia or significant pathological changes beyond reactive alterations were excluded from the study, supporting their use as appropriate non-neoplastic control tissues. Antibodies used Information on all the 69 antibodies used in the initial part of this study are provided in Supplementary Table 2. Sixteen were chosen for further investigation. Twelve antibodies recognising CD4, CD8, FOXP3, PD1, CD19, CD20, CD21, CD79a, CD79b, BCL2, BCL6, and CD163 were kindly donated by Abcam (Cambridge, UK) (as well as the other antibodies listed in the Supplementary Table 2) while antibodies recognising CD3, IRF4 and PAX5 were obtained from commercial companies. Anti-TOX2 was produced by our Monoclonal antibodies Unit at the Spanish National Cancer Research Centre (CNIO). Details of the 16 antibodies used for further study, including their use in other previous cross species studies, are shown in Table 2. Table 2Characteristicsof the antibodies used and immunohistochemical staining patterns inhuman lymph nodesAntibody/SupplierClone/TypeAntigen and/or epitopeExpressionApplications for useInformation provided by supplier on species studiedImmunolabelling results in human lymph node in current studyCD3Leica BiosystemsClone LN10Mouse IgG1MonoclonalRecombinant protein of C-terminal region of the human CD3 epsilon chainPan T-cell markerIHC-PHumanMembrane and cytoplasmic staining of small lymphocytes follicles and interfollicular areasCD4AbcamClone RM1013Rabbit IgG multiclonalSynthetic peptide -proprietary informationT-helper cellsIHC-P, IHC-F, ICC/IF, IP and WBHuman and mouseCytoplasmic staining of lymphocytes in the interfollicular areas with scattered positive germinal centre cellsCD8AbcamClone CAL66Rabbit IgG monoclonalSynthetic peptide aa 204–235 within human CD8aSuppressor/cytotoxic T-cellsIHC-P, IHC-Fr, ICC/IF, FC, IP, WB and mIHCHuman and ratCytoplasmic staining of lymphocytes in the interfollicular areas with scattered positive germinal centre cellsFOXP3AbcamClone 221DMouse IgG1 monoclonalRecombinant protein with epitope in amino-terminal of human FOXP3 protein 105–236Regulatory T-cellsIHC-P and WBHuman, mouse, dog, horse, rabbit, alpaca, sheep and pigNuclear staining in interfollicular areas with scattered positive cells in germinal centre cellsPD-1AbcamClone CAL20Rabbit IgG monoclonalSynthetic peptide -proprietary informationFollicular helper T-cellsIHC-P, ICC/IF, mIHC and WBHuman, mouse and ratMembrane and cytoplasmic staining in T-helper cells within germinal centre, with weaker expression in some T cells near folliclesTOX2CNIOTOM924DRat IgG2a monoclonalEpitope aa VVEAGK within human TOX2 full length recombinant proteinFollicular T-helper cells and NK cellsIHC-P, IHC-F, ICC/IF, IP and WBHuman and mouseNuclear staining in T helper cells within germinal centre, with weaker expression in some cells near folliclesCD19AbcamClone SP291Rabbit IgG monoclonalSynthetic peptide derived from the C-terminal region of human CD19B-cells from early stages development to mature B-cells, not plasma cellsIHC-P, IHC-F, ICC/IF, mIHC, FC, IP and WBHumanMembrane staining with strong labelling of germinal centre, mantle zone and interfollicular B-cellsCD20AbcamClone SP32Rabbit IgG monoclonalSynthetic peptide from aa 250 to end of CD20 proteinB-cells from early stages development to mature B-cells, not plasma cellsIHC-P, IHC-F, ICC/IF, mIHC, FC, IP and WBHuman, mouse and ratMembrane staining with strong labelling of germinal centre, mantle zone and interfollicular B-cellsCD21AbcamClone SP186Rabbit IgG monoclonalSynthetic peptide -proprietary informationMature B-cells and follicular dendritic cellsIHC-P, IHC-F, ICC/IF, FC and WBHuman, mouse and ratMembrane staining in mantle zone B cells with dense reticular staining in germinal centresCD79aAbcamClone riGA/764Mouse IgG1 monoclonalRecombinant full length CD79a proteinB-cells from early committed B-cells to plasma cellsIHC-PHumanCytoplasmic staining in lymphoid follicles, with increased labelling in interfollicular B cells and plasmacytoid cells in interfollicular areasCD79bAbcamClone EPR6861Rabbit IgG monoclonalSynthetic peptide -proprietary informationB-cells from early committed B-cells to mature B-cellsIHC-P, IHC-F, ICC/IF, FC and WBHuman, mouse and ratCytoplasmic staining in lymphoid follicles, with stronger labelling in germinal centre and mantle zone B cellsBCL-2AbcamClone 100/D5Mouse IgG1 monoclonalaa 41–54 of human BCL-2 GAAPAPGIFSSQPG-CysT-cells, pro-B cells and mature B-cells (where lifespan is extended) but downregulated in germinal centre B-cellsIHC-P, IHCC, ICC/IF, FC and WBHuman and mouseCytoplasmic staining in mantle zone B cells and interfollicular T cellsBCL-6AbcamClone GI191Mouse IgG1 monoclonalpCDNA3-BCL6 plasmid vector (full-length sequence of human BCL6)Germinal centre B-cells and some T-cellsIHC-P, IP and WBHuman, mouse and ratNuclear staining of germinal centre B cellsMUM1/IRF-4DAKOClone MUM1pMouse IgG1, k monoclonalaa 144 to 451 of the human MUM1 recombinant proteinB-cells at late stages differentiation and in plasma cellsIHC-P, ICC/IF and WBHumanNuclear staining in late germinal centre B cells and in interfollicular plasma cellsPAX5DAKOClone Dak-PAX5Mouse IgG1, k monoclonalSynthetic 17-meric peptide from the C-terminal inhibitory domain of the PAX5 proteinB-cells from early development to mature B cells, absent in plasma cellsIHC-P, IHC-F, ICC/IF, IP and WBHumanNuclear staining in the mantle zone, weaker in the germinal centre and marginal zoneCD163AbcamClone EPR19518Rabbit IgG monoclonalRecombinant fragment-proprietary informationMonocytes and macrophagesIHC-P, IHC-F, ICC/IF, mIHC and WBHuman, mouse and ratCytoplasmic staining of interfollicular macrophages and sinus histiocytes Table 2Characteristicsof the antibodies used and immunohistochemical staining patterns inhuman lymph nodesAntibody/SupplierClone/TypeAntigen and/or epitopeExpressionApplications for useInformation provided by supplier on species studiedImmunolabelling results in human lymph node in current studyCD3Leica BiosystemsClone LN10Mouse IgG1MonoclonalRecombinant protein of C-terminal region of the human CD3 epsilon chainPan T-cell markerIHC-PHumanMembrane and cytoplasmic staining of small lymphocytes follicles and interfollicular areasCD4AbcamClone RM1013Rabbit IgG multiclonalSynthetic peptide -proprietary informationT-helper cellsIHC-P, IHC-F, ICC/IF, IP and WBHuman and mouseCytoplasmic staining of lymphocytes in the interfollicular areas with scattered positive germinal centre cellsCD8AbcamClone CAL66Rabbit IgG monoclonalSynthetic peptide aa 204–235 within human CD8aSuppressor/cytotoxic T-cellsIHC-P, IHC-Fr, ICC/IF, FC, IP, WB and mIHCHuman and ratCytoplasmic staining of lymphocytes in the interfollicular areas with scattered positive germinal centre cellsFOXP3AbcamClone 221DMouse IgG1 monoclonalRecombinant protein with epitope in amino-terminal of human FOXP3 protein 105–236Regulatory T-cellsIHC-P and WBHuman, mouse, dog, horse, rabbit, alpaca, sheep and pigNuclear staining in interfollicular areas with scattered positive cells in germinal centre cellsPD-1AbcamClone CAL20Rabbit IgG monoclonalSynthetic peptide -proprietary informationFollicular helper T-cellsIHC-P, ICC/IF, mIHC and WBHuman, mouse and ratMembrane and cytoplasmic staining in T-helper cells within germinal centre, with weaker expression in some T cells near folliclesTOX2CNIOTOM924DRat IgG2a monoclonalEpitope aa VVEAGK within human TOX2 full length recombinant proteinFollicular T-helper cells and NK cellsIHC-P, IHC-F, ICC/IF, IP and WBHuman and mouseNuclear staining in T helper cells within germinal centre, with weaker expression in some cells near folliclesCD19AbcamClone SP291Rabbit IgG monoclonalSynthetic peptide derived from the C-terminal region of human CD19B-cells from early stages development to mature B-cells, not plasma cellsIHC-P, IHC-F, ICC/IF, mIHC, FC, IP and WBHumanMembrane staining with strong labelling of germinal centre, mantle zone and interfollicular B-cellsCD20AbcamClone SP32Rabbit IgG monoclonalSynthetic peptide from aa 250 to end of CD20 proteinB-cells from early stages development to mature B-cells, not plasma cellsIHC-P, IHC-F, ICC/IF, mIHC, FC, IP and WBHuman, mouse and ratMembrane staining with strong labelling of germinal centre, mantle zone and interfollicular B-cellsCD21AbcamClone SP186Rabbit IgG monoclonalSynthetic peptide -proprietary informationMature B-cells and follicular dendritic cellsIHC-P, IHC-F, ICC/IF, FC and WBHuman, mouse and ratMembrane staining in mantle zone B cells with dense reticular staining in germinal centresCD79aAbcamClone riGA/764Mouse IgG1 monoclonalRecombinant full length CD79a proteinB-cells from early committed B-cells to plasma cellsIHC-PHumanCytoplasmic staining in lymphoid follicles, with increased labelling in interfollicular B cells and plasmacytoid cells in interfollicular areasCD79bAbcamClone EPR6861Rabbit IgG monoclonalSynthetic peptide -proprietary informationB-cells from early committed B-cells to mature B-cellsIHC-P, IHC-F, ICC/IF, FC and WBHuman, mouse and ratCytoplasmic staining in lymphoid follicles, with stronger labelling in germinal centre and mantle zone B cellsBCL-2AbcamClone 100/D5Mouse IgG1 monoclonalaa 41–54 of human BCL-2 GAAPAPGIFSSQPG-CysT-cells, pro-B cells and mature B-cells (where lifespan is extended) but downregulated in germinal centre B-cellsIHC-P, IHCC, ICC/IF, FC and WBHuman and mouseCytoplasmic staining in mantle zone B cells and interfollicular T cellsBCL-6AbcamClone GI191Mouse IgG1 monoclonalpCDNA3-BCL6 plasmid vector (full-length sequence of human BCL6)Germinal centre B-cells and some T-cellsIHC-P, IP and WBHuman, mouse and ratNuclear staining of germinal centre B cellsMUM1/IRF-4DAKOClone MUM1pMouse IgG1, k monoclonalaa 144 to 451 of the human MUM1 recombinant proteinB-cells at late stages differentiation and in plasma cellsIHC-P, ICC/IF and WBHumanNuclear staining in late germinal centre B cells and in interfollicular plasma cellsPAX5DAKOClone Dak-PAX5Mouse IgG1, k monoclonalSynthetic 17-meric peptide from the C-terminal inhibitory domain of the PAX5 proteinB-cells from early development to mature B cells, absent in plasma cellsIHC-P, IHC-F, ICC/IF, IP and WBHumanNuclear staining in the mantle zone, weaker in the germinal centre and marginal zoneCD163AbcamClone EPR19518Rabbit IgG monoclonalRecombinant fragment-proprietary informationMonocytes and macrophagesIHC-P, IHC-F, ICC/IF, mIHC and WBHuman, mouse and ratCytoplasmic staining of interfollicular macrophages and sinus histiocytes Characteristicsof the antibodies used and immunohistochemical staining patterns inhuman lymph nodes CD3 Leica Biosystems Clone LN10 Mouse IgG1Monoclonal CD4 Abcam Clone RM1013 Rabbit IgG multiclonal CD8 Abcam Clone CAL66 Rabbit IgG monoclonal FOXP3 Abcam Clone 221D Mouse IgG1 monoclonal PD-1 Abcam Clone CAL20 Rabbit IgG monoclonal TOX2 CNIO TOM924D Rat IgG2a monoclonal CD19 Abcam Clone SP291 Rabbit IgG monoclonal CD20 Abcam Clone SP32 Rabbit IgG monoclonal CD21 Abcam Clone SP186 Rabbit IgG monoclonal CD79a Abcam Clone riGA/764 Mouse IgG1 monoclonal CD79b Abcam Clone EPR6861 Rabbit IgG monoclonal BCL-2 Abcam Clone 100/D5 Mouse IgG1 monoclonal BCL-6 Abcam Clone GI191 Mouse IgG1 monoclonal MUM1/IRF-4 DAKO Clone MUM1p Mouse IgG1, k monoclonal PAX5 DAKO Clone Dak-PAX5 Mouse IgG1, k monoclonal CD163 Abcam Clone EPR19518 Rabbit IgG monoclonal Tissue fixation Tissue samples were collected and immediately fixed to minimize autolysis and preserve cellular structure. Formaldehyde 3.7–4.0% methanol (PANREAC; 252931.1214) was used as the fixative. To ensure proper penetration, tissues were trimmed to ≤ 2 mm thickness and immersed in a fixative volume at least 15 times their size. Fixation was done at room temperature for at least 24 h, extended to up to 72 h if needed. After fixation, tissues were processed and embedded in paraffin by gradually replacing water with alcohol, xylene and paraffin over 14 h. Samples were then cut into 2.5 μm sections, mounted on Superfrost® Plus slides, and dried overnight. Several multiblocks were prepared, each containing tissue samples from six different species. These samples were selected based on regions previously identified by a pathologist using haematoxylin and eosin-stained slides. The multiblocks were constructed using representative tissue areas embedded into new paraffin blocks, each multiblock also containing a portion of human tonsil as a positive control to evaluate antibody performance during IHC analysis. Immunohistochemical labelling The BOND Polymer Refine Detection System on the Bond RX Automated Stainer (DS9800, Leica Biosystems, Wetzlar, Germany) was used for immunohistochemical labelling of FFPE tissues. The protocol included a peroxide block, post-primary reagent, polymer detection, 3,3′-diaminobenzidine (DAB) chromogen, and haematoxylin counterstain, all automated to minimize variability. Antigen retrieval was performed by heat-induced epitope retrieval (HIER) for 20 min in Tris-EDTA buffer (BOND Epitope Retrieval Solution 2, AR9640, Leica Biosystems, Wetzlar, Germany). For mouse and rabbit antibodies, the staining sequence comprised a peroxide block (3% hydrogen peroxide, 10 min), primary antibody incubation (30 min), post-primary (10 min), polymer (10 min), DAB (10 min) and haematoxylin (8 min). For rat-derived primary antibodies, a species-specific secondary detection step was included to ensure specificity and minimize non-specific binding. After primary antibody incubation, sections were incubated with a biotinylated rabbit anti-rat IgG (H + L), mouse-adsorbed secondary antibody (BA-4001, Vector Laboratories, California, USA) at a 1:300 dilution for 20 min, followed by polymer incubation for 15 min. In the case of mouse tissues, a modified IHC protocol was employed to minimize background staining potentially caused by cross-reactivity with anti-mouse secondary antibodies. Antigen retrieval was performed using either low-pH (PAX5) or high-pH (CD3, CD4, CD8a, FOXP3, PD1, TOX2, CD19, CD20, CD21, CD79a, CD79b, BCL2, BCL6, IRF4, and CD163) buffers (Dako, Agilent), followed by blocking of endogenous peroxidase activity with 3% hydrogen peroxide for 5 min. Slides were then incubated with the primary antibody for 25 min, followed, when required, by incubation with an unconjugated rabbit anti-mouse secondary antibody diluted 1:500 (Abcam, ab226129). This secondary antibody binds to the mouse primary antibody and is subsequently recognized by an HRP-conjugated polymer containing anti-rabbit IgG (Novolink Polymer, Leica; post-polymer step omitted), thereby minimizing nonspecific binding to mouse tissue. Detection of antigen–antibody complexes was performed using this HRP-polymer system. Staining was developed using DAB for 10 min (EnVision FLEX DAB Enhancer, Dako, Agilent), and nuclei were counterstained with hematoxylin for 5 min (FLEX Hematoxylin, SM806, Dako, Agilent). Images were acquired using an Axiocam CCD camera (Zeiss) at 40x magnification and processed with ZEN 2.1 software and Photoshop 9.0. Negative controls were routinely included in all immunohistochemical experiments by omitting the primary antibody. These controls consistently showed no specific or non-specific background staining, thereby confirming the specificity of the immunolabelling. A pathologist carefully examined the stained tissue sections under a light microscope to verify that staining was correctly localized within the expected regions of each tissue, using human tonsil as a reference. The intensity of IHC staining was then assessed using a standardized semi-quantitative scale: +++ for strong, ++ for moderate, + for weak staining and - for absence of staining. This consistent scoring system ensures reliable comparison of staining patterns across all samples. Results A total of 69 antibodies (28 mouse, 10 rat, 30 rabbit Mabs and 1 rabbit multiclonal antibody) previously published as specific for antigens present on lymphoid cells, monocytes and macrophages were studied for their ability to work in IHC on animal species. Their details are listed in Supplementary Table 2. All were tested on FFPE tissue sections from lymphoid tissues from 13 domestic and 28 wild/exotic animal species and details are listed in Supplementary Table 1. Of the 69 antibodies tested, 20 demonstrated promising cross-reactivity. Three pairs of antibodies were found to target BCL2, CD79a or PD-1. Although all antibodies exhibited effective and specific staining suitable for IHC, the one with the most consistent and strongest signal for each antigen was selected for inclusion in the final panel. Consequently, the final panel comprises the 16 antibodies listed in Table 2. The immunostaining results from testing these antibodies on FFPE sections of human lymph node are described in Table 3 to enable a comparison with the results obtained from the other animals in this study. The results of the IHC studies on the whole range of animal species are listed in Table 3. Staining intensity was classified as strong (+++), moderate (++), weak (+) or (-) absence of staining. In some cases, staining could not be evaluated (NE), either due to the absence of germinal centres or other factors that precluded the accurate determination of immunoexpression.Table 3Reactivity of antibodies against immune cell markers in various domestic and wild/exotic animal species Table 3Reactivity of antibodies against immune cell markers in various domestic and wild/exotic animal species Reactivity of antibodies against immune cell markers in various domestic and wild/exotic animal species Application of the antibody panel to human and animal tissues demonstrated consistent immunolabelling patterns across a broad range of species. Representative staining in human tonsil and mouse tissues is shown in Fig. 1 (human tonsil and mouse). Immunolabelling in domestic mammalian species is presented in Fig. 2 (rat and cat), Fig. 3 (dog and horse), Fig. 4 (pig and llama), Fig. 5 (cow and goat), and Fig. 6 (sheep). Fig. 1Immunolabelling results in human tonsil and mouse lymph node (40x magnification) Immunolabelling results in human tonsil and mouse lymph node (40x magnification) Fig. 2 Immunolabelling results in rat and cat lymph node (40x magnification) Immunolabelling results in rat and cat lymph node (40x magnification) Fig. 3Immunolabelling results in dog and horse lymph node (40x magnification) Immunolabelling results in dog and horse lymph node (40x magnification) Fig. 4Immunolabelling results in pig and llama lymph node (40x magnification) Immunolabelling results in pig and llama lymph node (40x magnification) Fig. 5Immunolabelling results in cow and goat lymph node (40x magnification) Immunolabelling results in cow and goat lymph node (40x magnification) Fig. 6Immunolabelling results in sheep lymph node (40x magnification) Immunolabelling results in sheep lymph node (40x magnification) Wild and exotic mammalian species are illustrated in Figs. 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16, including primates, carnivores, and ungulates: Fig. 7 (baboon), Fig. 8 (mandrill), Fig. 9 (Bornean gibbon), Fig. 10 (brown lemur and Patagonian mara), Fig. 11 (badger and giant otter), Fig. 12 (raccoon and Asian black bear), Fig. 13 (grey wolf and South American sea lion), Fig. 14 (reindeer, Chinese muntjac, and fallow deer), Fig. 15 (wild boar, red river hog, and European bison), and Fig. 16 (sitatunga and Dorcas gazelle). Avian species are presented separately: Fig. 17 (chicken, tumbler pigeon, and canary), Fig. 18 (emu, black swan, Jacobin pigeon, American flamingo, and black-footed penguin), and Fig. 19 (white stork, sacred ibis, common barn owl, and snowy owl). Fig. 7Immunolabelling results in baboon lymph node (40x magnification) Immunolabelling results in baboon lymph node (40x magnification) Fig. 8Immunolabelling results in mandril lymph node (40x magnification) Immunolabelling results in mandril lymph node (40x magnification) Fig. 9Immunolabelling results in Bornean gibbon spleen (40x magnification) Immunolabelling results in Bornean gibbon spleen (40x magnification) Fig. 10Immunolabelling results in brown lemur and Patagonian mara lymph node (40x magnification) Immunolabelling results in brown lemur and Patagonian mara lymph node (40x magnification) Fig. 11Immunolabelling results in badger and giant otter lymph node (40x magnification) Immunolabelling results in badger and giant otter lymph node (40x magnification) Fig. 12Immunolabelling results in racoon and Asian black bear lymph node (40x magnification) Immunolabelling results in racoon and Asian black bear lymph node (40x magnification) Fig. 13Immunolabelling results in grey wolf spleen and South American sea lion lymph node (40x magnification) Immunolabelling results in grey wolf spleen and South American sea lion lymph node (40x magnification) Fig. 14Immunolabelling results in reindeer lymp node, Chinese muntjac spleen and fallow deer lymph node (40x magnification) Immunolabelling results in reindeer lymp node, Chinese muntjac spleen and fallow deer lymph node (40x magnification) Fig. 15Immunolabelling results in wild boar, red river hog and European bison lymph node (40x magnification) Immunolabelling results in wild boar, red river hog and European bison lymph node (40x magnification) Fig. 16Immunolabelling results in sitatunga and dorcas gazelle lymph node (40x magnification) Immunolabelling results in sitatunga and dorcas gazelle lymph node (40x magnification) Fig. 17Immunolabelling results in chicken Bursa of Fabricius and tumbler pigeon and canary spleen (40x magnification) Immunolabelling results in chicken Bursa of Fabricius and tumbler pigeon and canary spleen (40x magnification) Fig. 18Immunolabelling results in emu, black swan, Jacobin pigeon, American flamingo, and black footed penguin spleen (40x magnification) Immunolabelling results in emu, black swan, Jacobin pigeon, American flamingo, and black footed penguin spleen (40x magnification) Fig. 19Immunolabelling results in white stork, sacred ibis, common barn owl, and snowy owl spleen (40x magnification) Immunolabelling results in white stork, sacred ibis, common barn owl, and snowy owl spleen (40x magnification) Antibodies of particular interest were anti-CD3 (LN10) and anti-CD79b (EPR6861) recognising T-cells and B-cells, respectively. Both antibodies produced strong labelling of T- or B-cells in all the mammalian and avian species studied here. Anti-PAX5 (DAK-Pax5) stained the nuclei of B cells in 28/29 mammalian species and in 8/12 avian species, respectively. Labelling with the anti-CD20 (SP32) was detected 19/29 of the mammalian species. Anti-CD79a (riGA/764) stained B-cells in 24/29 mammal species in two avian species, the emu and Jacobin pigeon. In contrast, anti-CD19 (SP291) recognised B-cells in all 12 avian species studied but only 9/29 in tissues from the mammalian species. Anti-BCL-2 (100/D5) stained the nuclei of B-cells in 13/29 mammalian species but no avian tissues. Anti-BCL6 (GI191) labelled the nuclei of B-cells in 15/21 mammalian species. The evaluation of BCL-6 was, however, hindered by the absence of clearly identifiable germinal centres within the samples. Although IRF4 is expressed in activated B- and T-cells, it was included as a target antigen here as it is expressed by plasma cells. Anti-IRF4 (MUM11p) stained the nuclei of plasma cells in 12/29 mammalian and 8/12 avian species. Antibodies recognising T-cell subpopulations were also tested. Anti-CD8 (CD8-CAL66) labelled cytotoxic T-cells in 18/29 mammalian tissues studied while anti-FOXP3 (FOXP3-22D1) stained regulatory T cells in 17/29 mammalian tissues. Anti-CD4 (CD4-RM1013) showed a more limited staining distribution with helper-T cells being recognised in 9/29 mammalian species. Importantly, antibodies directed to CD4, CD8 and FOXP3 were unable to recognise their antigens in any evaluable avian tissues. Anti-PD-1 (PD-1-CAL20) and anti-TOX2 (TOX2-TOM924D) detected follicular helper-T cells in evaluable tissues from 10/22 to 14/22 mammalian species, respectively. Unfortunately, the results from both using (PD1-CAL20) and anti-TOX2 (TOX2-TOM924D) were unable to be scored in the avian tissues studied. Anti-CD21 (SP186) labelled a subset of B cells and follicular dendritic cells in 16/29 mammalian species. Neither antibody labelled cells in any of the avian species studied, further highlighting a gap in available myeloid markers for birds. Throughout the examined species, the anti-CD163 antibody (EPR19518) consistently labelled multiple macrophage populations, including sinus histiocytes, tingible body macrophages, interfollicular and subepithelial macrophages, and interstitial macrophages. The staining pattern varied across species. In most species investigated, both domestic and wild/exotic, two distinct CD163⁺ cell morphologies were identified: large, rounded cells corresponding to tissue and interstitial macrophages, and stellate to fusiform cells, likely representing interstitial dendritic cell. Staining of tingible body macrophage was evident in some species, however, this could not be conclusively confirmed in others due to the limited presence of germinal centres and tingible body macrophages in the tissue analysed. In the grey wolf and Dorcas gazelle, staining was restricted to sinus histiocytes and was absent in interstitial dendritic cells. Fifteen of the sixteen antibodies raised against human epitopes recognised haematopoietic cells in mandrill, baboon and gibbon. The remaining antibody studied, anti-CD19 (SP291), stained B-cells in the Bornean gibbon. This wide cross-reactivity pattern contrasts with the absence of staining with antibodies targeting CD4, CD8, FOXP3, CD20, BCL2 and CD163 in any avian species tested. Discussion Immunophenotyping plays a key role in the diagnosis and classification of lymphomas. Determining the exact cell phenotype improves diagnostic accuracy, prognosis and supports the development of individualized therapies. Approximately 75% of veterinary oncologists include it in routine diagnostics, thus underscoring its clinical value. While basic B/T-cell distinction is achievable in most labs, accurate subtyping and the full characterisation of lymphoid and haematopoietic neoplasms require expanded antibody panels and immunopathology expertise [37]. This study aimed to identify such a panel of antibodies that could be used to study immune cell populations in clinical and research veterinary studies in a range of diverse animal species. Previously, many antibodies exhibited limited effectiveness, working best with fresh tissue. Polyclonal antibodies were commonly used in routine diagnostics as they enhanced sensitivity by targeting multiple epitopes, but variability between different antibody batches lead to problems in reproducibility [38]. Another difficulty was tissue fixation. Formalin was a commonly used since it preserved cellular morphology and tissue architecture, but many antibodies failed to recognise their target antigens in FFPE tissues [6, 8]. The production of monoclonal antibodies combined with advances in antigen retrieval techniques in IHC has increased the reliable detection of epitopes in FFPE fixed human [39] and animal tissues [5]. These developments have also provided opportunities for obtaining information from retrospective as well as prospective IHC studies. In the present study 16 antibodies raised against human antigens were found to cross react with haematopoietic tissues from a wide range of domesticated and wild/exotic animal species. The specificity of each antibody was assessed by matching positive immunoreactions with the expected T- or B-cell areas and labelling patterns in human lymphoid tissues. Well established immunostaining techniques were used [38]. A pathologist played a key role in evaluating and interpreting immunolabelling in both human and animal samples, ensuring that the observed reactivity was consistent with the expected protein expression and tissue architecture. In general, antibodies produced against the intracellular portion of a molecule tend to recognize conserved regions that remain relatively unchanged across different animals [4]. In this study we reported the interspecies reactivity of antibodies raised against intracytoplasmic peptide sequences from the haematopoietic CD3, CD5, mb-1 (now CD79a) and B29 (now CD79b) antigens. This was true for antibodies in the current study where known sequence data on the immunogen showed the relevant epitope was present across a wide range of species thus increasing the possibility that the antibodies exhibited broad species cross-reactivity across species [4, 40]. An additional advantage of intracytoplasmic epitopes is their ability to be less affected by formalin fixation. One of the important results from this study was the identification of antibodies that recognised the pan T-cell marker CD3 and the B-cell CD79b marker expressed across the wide range of both mammalian and avian species investigated. The broad cross reactivity of the anti-CD3 (LN10) and anti-CD79b (EPR6861) suggests that the epitopes recognized by these antibodies are largely conserved, reflecting a preserved immune architecture across species. Species-specific variability with other antigens was also observed with closely related species showing greater similarity in their immunolabelling results. The current results support the utility of using antibodies in non-human primate research. Although multiple studies have reported the use of cross-reactive antibodies recognising the T-cell CD3 and/or B-Cell CD79a antigens [4, 8, 9, 12, 17, 25, 30, 41], antibodies to the B-cell specific CD79b marker have been little reported in veterinary studies [4, 7]. Despite CD79b being absent from plasma cells, the use of anti-CD79b (EPR6861) here had the advantage over anti-CD79a (riGA/764) as it labelled B-cells in more species, including all the avian species studied. Although Kurokawa et al. [5] reported the absence of CD79a in avian cells, the anti-CD79a (riGA/764) used here labelled emu and Jacobin pigeon B-cells. The current study identified antibodies recognising the CD19 and CD20 B-cell associated antigens, both well established as important immunohistochemical and flow cytometry tools in veterinary pathology [25, 37]. CD20 is a transmembrane protein predominantly expressed on mature B-cells and is widely utilized for detecting B-cell lymphomas in canines [25, 37]. Anti-CD20 (SP32), besides labelling canine B-cells also recognised B-cells from a variety of wild/exotic mammals. The CD19 cell surface receptor is more widely expressed being present from the early stages of B-cell development to plasma cells and has also been used in canine studies [23, 24]. However, CD19 expression has been mainly investigated by flow cytometry rather than using IHC. One possible explanation being that surface epitopes of the CD19 antigen are altered by routine fixation. The present study identified anti-CD19 (SP291) as an antibody that recognizes a formalin-resistant epitope and shows cross-reactivity across multiple animal species, thereby providing opportunities for broader application in veterinary IHC studies. Although anti-CD20 (SP32) was able to immunolabel cells in a wider diversity of mammals than anti-CD19 (SP291), CD19 was detected in all 12 avian species studied. This highlights the critical importance of choosing the appropriate B-cell marker, CD19 or CD20, tailored to the species and context to ensure accurate diagnostic interpretation. There have been previous reports of problems using antibodies to CD20 and CD79a [5, 42, 43]. Results from the current study demonstrate that CD19 and CD79b, but not CD20 and CD79a, are valuable B-cell markers for the further avian studies. The transcription factors PAX5 and IRF4 have emerged as essential immunohistochemical markers for the classification of lymphoid neoplasms across animal species. PAX5 has demonstrated superior sensitivity to conventional markers such as CD79a, particularly in canine and feline lymphomas [28, 31, 44]. PAX5 has also been reported as a valuable marker in avian species [5] supporting its application in both diagnostic and comparative immunology. In our study, PAX5 was expressed in the B-cell nuclei of nearly all species analysed, including 8/12 avian species further highlighting the use of anti-PAX5 (DAK-Pax5) in veterinary clinical and research applications. IRF4, has been shown as a valuable marker of plasma cell tumours in dogs where it has shown strong nuclear and moderate cytoplasmic expression in over 90% of plasmacytomas thus offering superior sensitivity and specificity compared to traditional B-cell markers such as CD79a and CD20 [30]. In the current study, anti-IRF4 (MUM1p) stained canine tissues as well as 11/29 of the other mammalian species. Another advantage was that anti-IRF4 (MUM1p) detected IRF4 in most avian species studied, thereby facilitating the investigation of this marker in these species [45]. BCL6 and BCL2 have been reported as having potential utility in veterinary pathology, particularly for supporting lymphoma classification across species. BCL6, another transcription factor, typically expressed in germinal centre B-cells and has been most thoroughly investigated in canine lymphomas [46], where it plays a crucial role in differentiating specific lymphoma subtypes. In our study, BCL6 was detected in 15/41 animal species studied but its evaluation was hindered by the absence of clearly identifiable germinal centres within some tissue samples. Nevertheless, the detection of BCL6 remains a valuable indicator for germinal centre cells in veterinary studies. The apoptotic protein BCL-2 is another germinal cell marker used as a marker in the diagnosis and classification of lymphomas, particularly in dogs and cats [46, 47]. This expression pattern mirrors that observed in human pathology, reinforcing the relevance of studying BCL2 in comparative oncology across species. In the current study anti-BCL2 (100/D5) showed nuclear labelling in 13 of the mammalian species supporting its value in future veterinary studies. In contrast to previous findings, anti-BCL2 (100/D5) did not stain dog tissues. In contrast to the study by Curran et al. [47] who reported high levels of BCL-2 expression in normal canine tissues as well as in B-cell lymphomas, the anti-BCL2 (100/D5) used in the current study did not stain normal canine lymph node. The other BCL2 antibody candidate investigated in the current study (BCL2/1878R raised against full length BCL-2 protein in Supplementary Table 2) was tested again but did not detect BCL2 in the canine lymph node. Further studies are necessary to address the difference in BCL-2 expression. The ability to recognise T- cell subpopulations in veterinary practice significantly improves the accuracy in lymphoma subtyping and promotes increased understanding of the immune microenvironment. In veterinary oncology, CD4 and CD8 staining helps evaluate tumour-infiltrating lymphocytes [48], providing valuable prognostic information for cancers such as canine mammary tumours and lymphomas [49]. FOXP3 IHC plays an important role in detecting regulatory T-cell infiltration in inflammatory and autoimmune disease, which often correlates with immunosuppression and can influence prognosis in various cancers such as canine melanocytic tumours and mammary carcinomas [50]. The current study identified antibodies that can be used to identify CD4-positive helper T-cells, CD8-positive cytotoxic T-cells as well as FOXP3-positive regulatory T-cells in a wide variety of domestic and exotic mammals. None of these reagents, however, recognised their antigens in avian species. Our findings could be due to lack of validation of these antibodies, related to variability in avian CD4, CD8, and FOXP3 antigens, and further investigations are required to identify reagents suitable for IHC studies in avian tissues. Although PD-1 is a well-recognized immune checkpoint marker in human medicine, its application in veterinary species has not been fully explored. Previous studies have primarily focused on canine cancers [51] where PD-1 expression by circulating and tumour-infiltrating T cells has been linked to lymphoma and various epithelial tumours [46]. While these findings are promising, the broader diagnostic and research potential of PD-1 in other animal species remains under-investigated. The identification of anti-PD1 (CAL20) as a research tool opens possibilities to investigate the tumour microenvironment and other immune-mediated diseases offering insight into new therapeutic approaches in veterinary medicine. Furthermore, the detection of PD-1 and FOXP3 antigens on porcine cells is of particular interest as pigs can be used as animal models in the study of human disease. TOX2, a transcription factor expressed by human PD-1-positive T-cells and mature natural killer cells in human tissues [52, 53] has recently emerged as a novel marker of interest. The current results showing the ability of anti-TOX2 (TOM942) to label TOX2 in a variety of domestic and wild/exotic mammals should prove useful for identifying and characterizing specific immune cell subsets in veterinary pathology however, further studies are required to clarify the biological and diagnostic significance of this molecule in animals species [54]. CD21 is a widely recognized marker for B cells and FDCs in veterinary diagnostic IHC and flow cytometry studies across species such as dog, cat and sheep [54, 55]. It is a valuable marker for identifying B-cell lineage in canine lymphomas and leukaemia, helping differentiate B-cell from T-cell neoplasms [54]. Additionally, CD21 IHC is useful for highlighting normal FDCs and B-cells within lymphoid structures such as lymph nodes and tonsils. This dual role aids pathologists in evaluating the architecture and cellular composition of lymphoid tissues, crucial in differentiating reactive from neoplastic conditions. In the current study, anti-CD21 (SP186) labelled FDCs and B-cells in a variety of both domestic and wild/exotic species. Further study is, however, necessary to assess whether CD21 is present in avians. Although the anti-CD163 antibody (EPR19518) labelled multiple macrophage populations across multiple mammalian species, poorly defined staining or lack of CD163 expression in rat and mouse were observed. This is consistent with recent studies showing that MDMs do not express CD163 in these rodents, and that the typical CD163⁺ cells in these animals correspond to specific subpopulations of resident macrophages [56]. In grey wolf and Dorcas gazelle, staining was restricted to sinus histiocytes and was absent in interstitial dendritic cells. The lack of antibodies suitable for performing IHC in bird tissues presents a major problem for avian veterinary research and practice. A major result from the present study was the identification of a panel of antibodies to CD3, CD19, CD79b, IRF-4 and PAX5 recognising their antigen in most avian species studied. Notably, CD3, CD19 and CD79b were detected on all 12 bird species (including chicken) investigated, while IRF-4 and PAX5 were detected in tissues from at least 8 of the 12 species. The use of the CD19, CD79b and IRF-4 antibodies would, therefore, fulfil the need for a panel of B-cell specific antibodies previously reported by Kurokawa et al. [5]. Further studies are necessary to investigate the utility of PD1, TOX2, CD21 and BCL-6 expression in avian tissues. Immunolabeling has proven to be essential for determining the clinical outcome of certain lymphoma subtypes and establishing treatment protocols and chemotherapy both in humans and domestic animal species [57, 58]. Many wildlife species are also susceptible to lymphoma and other lymphoid and myeloid proliferative diseases. Records of lymphoma exist for Asian black bear [59], baboon [60], gibbon [61] and penguin [42, 43,{Schmidt, 2012 #72] and many other species or closely related species tested in this study. The inability to characterise the phenotype or classify the subtype of lesions in these animals often translates in having to extrapolate therapies standardized for other species without certain knowledge on the effects or prognosis. The antibodies described represent a panel of reagents which can be used in immunophenotyping studies on different haematopoietic cell populations across diverse animal species. Research using these antibodies should also enable research on immune traits linked to disease resistance thus promoting animal health and boost productivity and the worldwide welfare and treatment of animals. Conclusion The aim of the study was to identify antibodies showing promising cross-reactivity in a wide range of mammalian and avian species, providing a foundation for future species-specific validation. We have identified a panel of 16 antibodies able to recognise their specific antigens in IHC studies in FFPE tissues from 13 domestic and 28 wild/exotic animal species. The antibodies recognising CD3, CD19, CD79a, CD79b, IRF-4 and PAX5 antigens form the basis of a panel of antibodies for studying subpopulations of immune cells across a diverse range of both animal and avian species. One of the important outcomes was the identification of a panel of antibodies that could be used to immunophenotype avian species, an area previously lacking suitable reagent. Previous human and veterinary studies have used the results obtained from neoplastic cells and tissues to improve diagnosis, identify prognostic markers and new therapies. Our results focus on the immunoreactivity of antibodies in lymphatic tissues from mammalian and avian species and highlight the potential for these reagents also to be used in future studies on veterinary research and practice in addition to promoting animal welfare. Additionally, investigating the development and interaction of diverse immune cell populations provides valuable knowledge that can be harnessed for tissue repair and regenerative medicine. Supplementary Information Supplementary Material 1. Supplementary Table 1. List of species, taxonomic classification, and the lymphoid tissue analysed for each species. Supplementary Table 2. List of commercial antibodies used in this study. Supplementary Material 1. Supplementary Table 1. List of species, taxonomic classification, and the lymphoid tissue analysed for each species. Supplementary Table 2. List of commercial antibodies used in this study. Supplementary Material 2. Supplementary Material 2.